About 64x Bio
64x Bio is a company based in San Francisco (United States) founded in 2017 by David Thompson, Pamela Silver, Jeff Way, and George M Church. 64x Bio has raised $59.65 million across 3 funding rounds from investors including Lifeforce Capital, Northpond Ventures and Michael Chambers. The company has 18 employees as of December 31, 2022. 64x Bio offers products and services including End-to-End Platform. 64x Bio operates in a competitive market with competitors including Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
- Headquarter San Francisco, United States
- Employees 18 as on 31 Dec, 2022
- Founders David Thompson, Pamela Silver, Jeff Way, George M Church
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$59.65 M (USD)
in 3 rounds
-
Latest Funding Round
$55 M (USD), Series A
Jan 19, 2022
-
Investors
Lifeforce Capital
& 12 more
-
Employee Count
18
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 64x Bio
64x Bio offers a comprehensive portfolio of products and services, including End-to-End Platform.
Platform for designing scalable therapeutic systems efficiently.
People of 64x Bio
Unlock access to complete
Unlock access to complete
Funding Insights of 64x Bio
64x Bio has successfully raised a total of $59.65M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $55 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 64x Bio
64x Bio has secured backing from 13 investors, including venture fund and angel investors. Prominent investors backing the company include Lifeforce Capital, Northpond Ventures and Michael Chambers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Future Ventures is focused on early-stage venture capital investments.
|
Locked | Locked | Locked |
Investor details for 64x Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 64x Bio
Investment portfolio details for 64x Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 64x Bio
Detailed financials for 64x Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
64X Bio Comparisons
Peer comparison for 64x Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 64x Bio
64x Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| Locked | Locked | Locked |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Therapeutics for molecular-level cancer treatment are developed.
|
Detailed competitors of 64x Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 64X Bio
Complete news archive for 64x Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 64x Bio
64x Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
64x Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
64x Bio is a funded company, having raised a total of $59.65M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at 64x Bio is 18.
64x Bio was founded in 2017 in San Francisco, United States, within the biotechnology sector. Focus is placed on cell and gene therapy development for various disease treatments. A VectorSelect platform is utilized, incorporating DNA library synthesis, next-generation sequencing, and machine learning to design cells for biomanufacturing and therapeutic uses. Genome manipulation is employed to reprogram and edit DNA in organisms.
64x Bio's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
64x Bio offers End-to-End Platform.
64x Bio has 13 investors. Key investors include Lifeforce Capital, Northpond Ventures, Michael Chambers, Future Ventures, and First Round Capital.